Linperlisib Combined With Chidamide in Patients With PTCL

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The goal of this clinical trial is to determine the maximum tolerated dose (MTD) of PI3Kδ inhibitor linperlisib when combined with fixed dose of HDAC inhibitor chidamide in participants with peripheral T-cell lymphoma (PTCL), and to compare the combination of linperlisib and chidamide to standard CHOP (cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone) regimen chemotherapy in the frontline treatment of PTCL to see which therapy is better.
Epistemonikos ID: 9468b2455e6972cae68c37fd9bb33c99adeb8666
First added on: May 22, 2024